Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Re-visiting risk factors for cardiometabolic diseases: towards a new epidemiological frontier.

Frontiers in public health·2026
Same author

Comparative Efficacy of Continuous Versus Patch ECG Monitoring in Detecting Atrial Fibrillation Recurrence Post Catheter Ablation: Insights From the REAL-AF Registry.

Journal of cardiovascular electrophysiology·2026
Same author

Accuracy of a Deep Learning Model in Intracardiac Echocardiography.

JACC. Advances·2026
Same author

Explainable artificial intelligence models in predicting major cardiovascular events: insights from the PolyIran and PolyPars prospective studies.

Scientific reports·2026
Same author

DepoCatalog: mapping diversity of 129 recombinantly produced Klebsiella phage depolymerases.

Nature communications·2026
Same author

Artificial Intelligence-guided Extra-pulmonary Vein Repeat Ablation with the Pentaspline Pulsed Field Ablation Catheter.

The Journal of innovations in cardiac rhythm management·2026

Related Experiment Video

Updated: Jul 16, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K

Heart Failure: Recent Advances and Breakthroughs.

Sneha Annie Sebastian1, Edzel Lorraine Co2, Arun Mahtani3

  • 1Azeezia Medical College, Kollam, Kerala, India.

Disease-A-Month : DM
|September 13, 2023
PubMed
Summary

Novel therapies and artificial intelligence (AI) are improving outcomes for heart failure (HF) patients. This review covers new treatments and AI applications for early HF detection and risk stratification in heart failure with reduced ejection fraction (HFrEF).

Keywords:
AIGuideline-directed medical therapyHFrEFHeart failurePharmacotherapyPrecision medicineVericiguat

More Related Videos

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

785
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K

Related Experiment Videos

Last Updated: Jul 16, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

785
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K

Area of Science:

  • Cardiology
  • Medical Informatics

Background:

  • Heart failure (HF) poses a significant clinical and socioeconomic burden.
  • Recent pharmacotherapy advancements have reduced hospitalization and mortality in heart failure with reduced left ventricular ejection fraction (HFrEF).

Approach:

  • This review examines novel therapeutic agents and evidence-based goal-directed medical therapy (GDMT) for HF management.
  • It explores the integration of artificial intelligence (AI) and machine learning (ML) in HF care.

Key Points:

  • Newer pharmacotherapies are enhancing outcomes for HFrEF.
  • AI and ML show promise in early HF detection and risk stratification.
  • GDMT remains a cornerstone in managing heart failure.

Conclusions:

  • Advancements in pharmacotherapy and the application of AI/ML are transforming heart failure management.
  • These innovations offer improved cardiovascular disease outcomes, particularly for HFrEF patients.